Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
about
Low molecular weight heparins versus unfractionated heparin for acute coronary syndromesRisks and Benefits of Thrombolytic, Antiplatelet, and Anticoagulant Therapies for ST Segment Elevation Myocardial Infarction: Systematic ReviewAdjunctive treatment in patients treated with thrombolytic therapyThe role of antiplatelet therapy in the management of acute coronary syndromesGlycoprotein IIb/IIIa antagonism and fibrinolytic therapy for acute myocardial infarctionLow molecular weight heparins and glycoprotein IIb/IIIa antagonistsElevated troponin and myocardial infarction in the intensive care unit: a prospective study.Elderly patients with acute coronary syndromes: higher risk and greater benefit from antiplatelet therapy and/or interventional therapiesRole of abciximab in the treatment of coronary artery diseaseAcute ischemic heart disease and interventional cardiology: a time for pauseCatheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatmentFondaparinux in the management of patients with ST-elevation acute myocardial infarctionEnoxaparin in acute coronary syndromesEfficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS dataLow-molecular-weight heparins as adjunctive therapy to thrombolytics: extracting the best data.Unfractionated heparin: focus on a high-alert drug.Eptifibatide: The evidence for its role in the management of acute coronary syndromes.Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.Clinical review: bleeding - a notable complication of treatment in patients with acute coronary syndromes: incidence, predictors, classification, impact on prognosis, and managementThe exclusion of patients with chronic kidney disease from clinical trials in coronary artery diseaseSafety and effectiveness of enoxaparin following fibrinolytic therapy: Results of the Acute Myocardial Infarction (AMI)-QUEBEC registryClinical benefit of low molecular weight heparin for ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor.New advances in the management of acute coronary syndromes: 2. Fibrinolytic therapy for acute ST-segment elevation myocardial infarctionTenecteplase for treatment of acute myocardial infarction.Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium30-year trends in heart failure in patients hospitalized with acute myocardial infarction.Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions.Facilitated thrombolysis: dethrombosis?Administration of glycoprotein IIb-IIIa inhibitors in patients with ST-segment elevation myocardial infarction.Pharmacotherapeutic options for the management of myocardial infarction.Fibrinolytic and mechanical intervention trials in ST elevation acute myocardial infarction.Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease.Thrombolytics: prospects for new agents.Safety and efficacy of tenecteplase in acute myocardial infarction.Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome.Thrombolysis in elderly patients with acute myocardial infarction.Thrombolysis: newer thrombolytic agents and their role in clinical medicine.Recommendations on percutaneous coronary intervention for the reperfusion of acute ST elevation myocardial infarction.The role of low-molecular-weight heparins in cardiovascular medicine.Optimizing adjunctive antithrombotic therapy in the treatment of acute myocardial infarction: a role for low-molecular-weight heparin.
P2860
Q24250287-9D6C1C31-5A3B-46CB-B0B0-7AA9654A501FQ27026079-E7914653-11DD-4010-8C60-3A82B5595A57Q28168234-72F8FFFC-0350-48EE-8CFE-5EF6FE383AEDQ28176548-469360A3-BEBF-48DE-B91A-086F2C8F8185Q28193195-D39EEAB8-BDA5-4D22-9126-699EC17987E2Q28193196-17D7A4E0-2E32-44CA-BA0F-6C25EFC3A28BQ28193296-BA9E496E-DA1B-4EA7-80A7-5D15687FC767Q28196885-06DFE229-C8FD-4954-9CA0-4AD64F4B0B33Q28200177-052FAD89-6A06-4DE6-856D-44DBFCDAEE9CQ28200642-E21267EE-EFE6-4527-8347-7B47EB27C0D6Q28217792-E815B597-CA73-4D0A-98F3-8B508226F036Q28219415-106E77B2-9415-4585-AB0A-EEAB856FA9CBQ28301431-2A47CFE6-C818-4810-BE8E-2A681EAAE7F0Q31039791-5065C589-F68A-4A8E-8E41-73907598DBC3Q31039802-EFCC289F-D5EA-4550-A973-A5DA6750AC0CQ33362322-E8459676-A379-4BD7-967D-E23C5D7334F8Q33391279-021F9186-D817-4F50-A8BC-7853336AAA46Q33434702-A2B0EFF3-C9BC-40C9-A8A1-E032AE53326BQ33750028-3F04BD47-1A55-4057-8125-F4066A261B40Q34175429-75B1F35C-B988-477C-AB81-FDF4D4944A37Q34196711-5B0D52B8-0054-48D1-8BB3-BF171ABAB897Q34255603-BBC9B786-93E2-426F-A172-B61F521D747CQ34389738-71535F6D-CAEF-4C41-BB90-17C94A842EBCQ34417294-1EF80D6B-1593-4E66-9DC7-42B6D6A6E76CQ34492675-E4FDDE61-1D6A-4C19-B27B-CAFA0C5E9FF5Q34648516-80097EE6-365E-4FB3-86A3-B50D1F2A9BE6Q34660813-9D142033-49B9-4FFA-8D9D-A3A90721C059Q34743945-6B3F1460-052B-4771-B254-9D484B751A96Q34748832-D273F72C-2C47-4270-969D-B672B58F7AE8Q34768517-CD75374A-44A3-4D08-B902-F19A03A782FCQ34868156-492916DB-6A46-4549-AB4F-13BAFF1C042FQ35001049-3B6E8C7A-80C0-4593-857E-B48F6A004CAAQ35040756-5F65F583-54C9-4B9B-91BF-E3FC95FBFB80Q35124719-361AA567-3054-4166-98DE-EEE2105E472FQ35139249-FDCB2F05-97F4-4EC4-AFB2-5E7FA16CCABEQ35187891-F7B29C4C-7DD9-48E4-A4CF-393C1C99AC18Q35574270-98887323-F938-457E-93E0-9288429370F6Q35582491-A3C86933-EA0E-471C-AA1D-2B407EE61F18Q35591215-C43DC635-16E8-4063-88F6-E3B1B685FD79Q35638777-68817679-AA35-404F-8D90-6BD4B116C28D
P2860
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Efficacy and safety of tenecte ...... n acute myocardial infarction.
@en
Efficacy and safety of tenecte ...... n acute myocardial infarction.
@nl
type
label
Efficacy and safety of tenecte ...... n acute myocardial infarction.
@en
Efficacy and safety of tenecte ...... n acute myocardial infarction.
@nl
prefLabel
Efficacy and safety of tenecte ...... n acute myocardial infarction.
@en
Efficacy and safety of tenecte ...... n acute myocardial infarction.
@nl
P1433
P1476
Efficacy and safety of tenecte ...... n acute myocardial infarction.
@en
P2093
Assessment of the Safety and E ...... gimen (ASSENT)-3 Investigators
P304
P356
10.1016/S0140-6736(01)05775-0
P407
P577
2001-08-01T00:00:00Z